Novartis Australia and New Zealand Revenue and Competitors
Estimated Revenue & Valuation
- Novartis Australia and New Zealand's estimated annual revenue is currently $61.3M per year.
- Novartis Australia and New Zealand's estimated revenue per employee is $201,000
Employee Data
- Novartis Australia and New Zealand has 305 Employees.
- Novartis Australia and New Zealand grew their employee count by -6% last year.
Novartis Australia and New Zealand's People
| Name | Title | Email/Phone |
|---|
Novartis Australia and New Zealand Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $62.9M | 313 | 8% | N/A | N/A |
#2 | $26.5M | 132 | 7% | N/A | N/A |
#3 | $20.5M | 102 | 0% | N/A | N/A |
#4 | $18.3M | 91 | 6% | N/A | N/A |
#5 | $18.7M | 93 | 2% | N/A | N/A |
#6 | $72.2M | 359 | 6% | N/A | N/A |
#7 | $55.3M | 275 | 6% | N/A | N/A |
#8 | $35.8M | 178 | 6% | N/A | N/A |
#9 | $31M | 154 | 4% | N/A | N/A |
#10 | $70.8M | 352 | 5% | N/A | N/A |
What Is Novartis Australia and New Zealand?
Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. We have more than 60 years’ history in Australia and employ around 800 associates across our three divisions. We believe continued R&D is essential to innovation and in Australia we invest around 20M AUD annually in local clinical trials. Our mission is to discover new ways to improve and extend people’s lives.
keywords:N/A
N/A
Total Funding
305
Number of Employees
$61.3M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Novartis Australia and New Zealand News
Novartis is a focused medicines company, continuing to build depth in five ... Canada, Western Europe, Japan, Australia, and New Zealand...
Worldwide Adoptive Cell Therapy Industry to 2030 - Featuring Novartis, ... Australia; South Korea; ASEAN; Rest of Asia Pacific; Middle East...
... Announcement Big News for Australian Patients, and for Novartis ... Novartis' Zolgensma®, has become Australia's first gene therapy...
Other Companies in Blenheim Road
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $44.8M | 358 | 10% | N/A |
#2 | $155.9M | 378 | 7% | N/A |
#3 | $102.4M | 390 | -5% | N/A |
#4 | $35M | 431 | 1% | N/A |
#5 | $90.5M | 450 | 5% | N/A |